HNSBF - Hansa Biopharma divests its stake in Genovis and receives approval to commence imlifidase Phase 2 trial April, 15 2019 11:30 AM Hansa Biopharma AB Hansa Biopharma (OTC:HNSBF) divests its entire equity stake in Genovis (OTCPK:GEOVF) for SEK 89M (c.$9.6M).More news on: Hansa Biopharma AB, Genovis AB (publ), Healthcare stocks news, Read more ...